Markers of increased risk for failure of adjuvant therapies

Breast

Volumn 12, Issue 6, 2003, Pages 543-549

  Hayes, Daniel F ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Breast cancer; Predictive factors; Prognostic factors; Tumor markers

Indexed keywords

BIOLOGICAL MARKER; CATHEPSIN D; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR; PROTEIN P53;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER STATISTICS; CAREGIVER; CLINICAL TRIAL; FEMALE; HORMONAL THERAPY; HUMAN; META ANALYSIS; PATIENT ATTITUDE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SOCIAL ASPECT; TREATMENT FAILURE; WESTERN HEMISPHERE;

EID: 0347232439     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(03)00164-4     Document Type: Article

References (43)

1. Peto R, Boreham J, Clarke M, Davies C, Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 2000; 355: 1822.
2. Early Breast Cancer Trialist's Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451-1467.
3. Early Breast Cancer Trialist's Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 1998; 352: 930-942.
4. Knight W, Livingston R, Gregory E, McGuire W. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 1977; 37: 4669-4671.
5. Clark G, McGuire W, Hubay C, Pearson O, Marshall J. Progesterone receptors as a prognostic factor in stage II breast cancer. N Engl J Med 1983; 309: 1343-1347.
6. Slamon D J, Clark G M, Wong S G, Levin W J, Ullrich A, McGuire W L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
7. Tandon A, Clark G, Chamness G, Chirgwin J, McGuire W. Cathepsin D and prognosis in breast cancer. N Engl J Med 1990; 322: 297-302.
8. Weidner N, Semple P, Welch W, Folkman J. Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1-8.
9. Duffy M, O'Grady P, Devaney D, O'Siorain L, Fennelly J, Lijnen H. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Cancer 1988; 62: 531-533.
10. McGuire W L. Breast cancer prognostic factors: evaluation guidelines. J Natl Cancer Inst 1991; 83: 154-155.
11. Gasparini G. Prognostic variables in node-negative and node-positive breast cancer [editorial]. Breast Cancer Res Treat 1998; 52: 321-331.
12. Hayes D F, Trock B, Harris A. Assessing the clinical impact of prognostic factors: when is 'statistically significant' clinically useful? Breast Cancer Res Treat 1998; 52: 305-319.
13. Kuerer H M, Newman L A, Smith T L et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17: 460-469.
14. Fisher B, Bryant J, Wolmark N et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16: 2672-2685.
15. Mamounas E P. Overview of National Surgical Adjuvant Breast Project Neoadjuvant Chemotherapy Studies. Semin Oncol 1998; 6 (Suppl 3): 31-35.
16. Braun S, Kentenich C, Janni W et al. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol 2000; 18: 80-86.
17. Braun S, Schlimok G, Heumos I et al. ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I - III breast cancer patients. Cancer Res 2001; 61: 1890-1895.
18. Hayes D F, Walker T M, Singh B et al. Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer. Int J Oncol 2002; 21: 1111-1117.
19. Lippman M E, Allegra J C, Thompson E B et al. The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med 1978; 298: 1223-1228.
20. Henderson I C, Berry D, Demetri G D et al. Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose in an adjuvant chemotherapy regimen for patients with node positive primary breast cancer. J Clin Oncol 2003; 20: 976-983.
21. Trock B J, Yamauchi H, Brotzman M, Stearns V, Hayes D F. c-erbB-2 as a prognostic factor in breast cancer: a meta-analysis, Proc Am Soc Clin Oncol 2000; 19: 97a.
22. Yamauchi H, Stearns V, Hayes D F. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001; 19: 2334-2356.
23. Hayes D F, Bast R, Desch C E et al. A tumor marker utility grading system (TMUGS): a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996; 88: 1456-1466.
24. Hayes D F. Do we need prognostic factors in nodal-negative breast cancer? Arbiter. Eur J Cancer 2000; 36: 302-306.
25. Ravdin P M, Siminoff I A, Harvey J A. Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy. J Clin Oncol 1998; 16: 515-521.
26. Coates A S, Simes R J. Patient assessment of adjuvant treatment in operable breast cancer. In: Williams C J ed. Introducing New Treatments for Cancer: Practical, Ethical, and Legal Problems. New York, NY: John Wiley & Sons Ltd, 1992; 447-458.
27. Lindley C, Vasa S, Sawyer T, Winer E. Quality of life and preferences for treatment following systemic adjuvant therapy for early stage breast cancer. J Clin Oncol 1998; 16: 1380-1387.
28. Loprinzi C L, Thome S D. Understanding the utility of adjuvant systemic therapy for primary breast cancer. J Clin Oncol 2001; 19: 972-979.
29. Ravdin P M, Siminoff L A, Davis G J et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001; 19: 980-991.
30. Isaacs C, Stearns V, Hayes D F. New prognostic factors for breast cancer recurrence. Semin Oncol 2001; 28: 53-67.
31. Simon R, Altman D G. Statistical aspects of prognostic factor studies in oncology. Br J Cancer 1994; 69: 979-985.
32. Sobin L H, Wittekind C. TNM: Classification of Malignant Tumors. New York: Wiley-Liss, 2002.
33. American Joint Committee on Cancer t. AJCC Cancer Staging Manual. New York, Berlin, Heidelberg: Springer-Verlag, 2002.
34. Singletary S E, Allred C, Ashley P et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002; 20: 3628-3636.
35. Bast Jr R C, Ravdin P, Hayes D F et al. Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the american society of clinical-oncology. J Clin Oncol 2001; 19: 1865-1878.
36. Janicke F, Prechtl A, Thomssen C et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 2001; 93: 913-920.
37. Look M P, van Putten W L, Duffy M J et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002; 94: 116-128.
38. Harbeck N, Kates R E, Schmitt M. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J Clin Oncol 2002; 20: 1000-1007.
39. Foekens J A, Peters H A, Look M P et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 2000; 60: 636-643.
40. Harbeck N, Dettmar P, Thomssen C et al. Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up. Br J Cancer 1999; 80: 419-426.
41. Keyomarsi K, Tucker S L, Buchholz T A et al. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002; 347: 1566-1575.
42. van de Vijver M J, He Y D, van't Veer L J et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009.
43. Hayes D F. Clinical importance of prognostic factors: moving from scientifically interesting to clinically useful. In: Bronchud M H, Foote M, Peters W P, Robinson M O eds. Principles of Molecular Oncology. Totowa, NJ: Humana Press, Inc, in press.